Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

SDĚLENÍ

Ministerstva xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx a xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx nového xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx standard Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx sportu.

S xxxxx zněním Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx České xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Přílohy I xxxxxxxxx v xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku vstoupilo x xxxxxxxx xxx 18. xxxxxx 2024 x nahradilo Xxxxxxx X pro xxx 2023, xxxxxxx xx 1. ledna 2023, xxxxx vstoupila x xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Přílohy X pro rok 2024 x xxxx xxxxxxx xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. JUDr. Xxxxxx, Xx.X., LL.M., x. r.

vrchní xxxxxxx xxxxx právní a xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx xxxxxxx xx xxxxxxx jazyka

Úvod

Seznam xxxxxxxxxx xxxxx x xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx standard x xxxxx Světového antidopingového xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx po rozsáhlém xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxx xxxxxxxxx WADA a xxxx xxxxxxxxxx v xxxxxxxxxx x xxxxxxxxxxxxx. X případě xxxxxxxxxxx xxxxxxxxxxxxx xxxx anglickým x xxxxxxxxxxxx textem xxxxxxxxx znění x xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxx x tomto Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX pro daný xxxxx xxxxxxxxxxx xxxx xxxxxx, xx období Xxx soutěži x xxxxxx obdobím xxxxxxxxxxx xxxxx před půlnocí (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx se xx Xxxxxxxxx zúčastnit, xx xx konce Xxxxxxx a xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, xx xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Mimo xxxxxx, xxx xx xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Nespecifické

Podle xxxxxx 4.2.2 Xxxxxxxxx antidopingového Xxxxxx „pro účely xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx látkami, x xxxxxxxx xxxx xxxxxxxxxx x Seznamu xxxxxxxxxx xxxxx a xxxxx dopingu. Xxxxx Xxxxxxxx metoda xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx v Seznamu xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx xxxxxx.“ Podle xxxxxxxxx k xxxxxx „Xxxxxxxxxx látky a Xxxxxxxxxx metody xxxxxxx x článku 4.2.2 xx xxxxxx xxx xxxxxx způsobem xxxxxxxxxx xx méně xxxxxxxx xxxx xxxx xxxxxxxxxx xxx jiné dopingové xxxxx nebo xxxxxx. Xxx xxxxx x xxxxx a metody, xxxxx Sportovec pravděpodobně xxxx xxxx xxxxxx x xxxxxx účelu xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx jako xxxxx, xxxxx xxxx xxxx xxxxxx označeny x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx sportu. Xxxx Xxxxxxxx látky xxxx označovány tyto xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), methylendioxymetamfetamin (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (THC).

S0 XXXXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x této třídě xxxx Xxxxxxxxxx látky.

Jakákoliv xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx nevztahuje xxxxx x xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx xxxx x xxxxxxxx době xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx použití x xxxx (xxxx. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx vývoji xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxx (xxxx. Xxxxxxxxxxx x Tirasemtiv).

S1 ANABOLICKÉ XXXXX

XXXXXXXX STÁLE (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx zakázané xxxxx x této třídě xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx exogenním xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-hydroxy-5a-androst-1-en-17-on)		•	gestrinon
•	1-epiandrosteron (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (androst-4-en-3,17-dion)		•	norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		&xxxx;•	xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a xxxxx xxxxx s podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx biologickými účinky.

S1.2. XXXXXXX ANABOLICKÉ XXXXX

Xxxx xxxx včetně:

Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), LGD-4033 (ligandrol), XXX140, S-23 a XX-11], xxxxxxx x xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX FAKTORY, XXXXXXXX XXXXX A XXXXXXXX

XXXXXXXX XXXXX (PŘI SOUTĚŽI X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.

X2.1. ERYTROPOETINY (XXX) X LÁTKY XXXXXXXXXXX XXXXXXXXXXX

Xxxx jiné xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx a xxxxxx sloučeniny, např. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (HIF), např. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); roxadustat (XX-4592); xxxxxxxxxx (AKB-6548); xxxxx.

X2.1.3 Xxxxxxxxxx GATA, xxxx. X-11706.

X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx růstového xxxxxxx xxxx (XXX-β), např. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. xxxxxx EPO; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX XXXXXXX A XXXXXX UVOLŇUJÍCÍ FAKTORY

S2.2.1 Xxxxxxx xxxxxxxxxxx testosteron x mužů, mimo xxxx včetně:

• xxxxxxxx xxxxxxxxxxxx (XX),

• luteinizační xxxxxx (LH),

• xxxxxx xxxxxxxxxx gonadotropin (GnRH, xxxxxxxxxxx) x xxxx xxxxxxxxxxx analogy (např. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, nafarelin x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx x xxxxxx uvolňující faktory, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), jeho xxxxxxx x xxxxxxxxx, mimo xxxx xxxxxx:

• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx a xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, např. AOD-9604 x xXX 176–191.

S2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx xxxx xxxxxx:

• hormon xxxxxxxxxx xxxxxxx hormon (XXXX) x xxxx xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx a xxxxxxxxxxx,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x jejich xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, lenomorelin (ghrelin), xxxxxxxxxxx x xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), GHRP-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5 x XXXX-6].

X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• hepatocytový růstový xxxxxx (XXX)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX)

• thymosin-β4 x xxxx xxxxxxxx, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)

x xxxxx růstové faktory xxxx modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx syntézu/degradaci xxxxxxxx ve xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (PŘI SOUTĚŽI X MIMO XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx jsou Xxxxxxxxxx látky.

Všichni xxxxxxxxxx x xxxxxxxxxxxx beta-2 xxxxxxxx včetně xxxxx xxxxxxxxx izomerů jsou xxxxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x oddělených dávkách, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 hodin xx xxxxxxxxx xxxxx;

• xxxxxxxxx xxxxxxxxxx: maximálně xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 hodin;

• xxxxxxxxx vilanterol: xxxxxxxxx 25 mikrogramů xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxx xxxxxx xxx 1000 xx/xx nebo xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx x xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález (XXX), xxxxx Sportovec xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx xx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx S4.1 a X4.2 jsou Specifické xxxxx.

Xxxxx zařazené xx xxxx X4.3 x X4.4 xxxx Nespecifické xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx modulátory xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx včetně:

•	2-androstenol (5ɑ-androst-2-en-17-ol)		•	androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]

Xxxx jiné včetně:

•	arformoterol		•	indakaterol		•	reproterol		•	tretoquinol (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx jiné včetně:

•	protilátky xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx receptoru xxxxxxxx XXX, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx myostatinu
	- xxxxxxx receptory aktivinu (xxxx. XXX-031)			- proteiny xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, propeptid myostatinu)
•	protilátky xxxxx xxxxxxxxx aktivinu XXX (např. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx myostatin xxxx prekurzory (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté peroxizomovými xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (XXXXδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (GW1516, XX501516) x xxxxxxxx Xxx-xxxɑ , xxxx. SR9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX SOUTĚŽ)

Všechny zakázané xxxxx v této xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Diuretika, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx xxxxxxxxxx; furosemid; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. konivaptan, mozavaptan, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, např.:

albumin, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Desmopresin;

• Probenecid;

a xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx podobnými biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x lokální xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, brinzolamid);

• xxxxxxx xxxxxx felypresinu x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx xxxxxxxx látky xx stanoveným prahovým xxxxxxx: x formoterolu, xxxxxxxxxxx, katinu, efedrinu, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx (kromě xxxxxxxxx xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx xxxx lokálního xxxxxx felypresinu v xxxxxxxx anestezii), bude xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx (AAF), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) na xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx x xxxx třídě xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x X2.2, xxx jsou Specifické xxxxxx.

X1. XXXXXXXXXX S XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx následující:

M1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx s xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx složek Sportovci xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x xxxxxxxxxxxxx odběrovém xxxxxx.

X1.2. Xxxxx zvyšování xxxxxx, xxxxxxx xxxx xxxxxxx kyslíku.

Mimo xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (RSR13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx produkty, xxxx. xxxxxx xxxxxxxx na xxxx xxxxxxxxxxx a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx produkty, x výjimkou xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x krví nebo x xxxxxxxx komponentami xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. CHEMICKÁ A XXXXXXXXX MANIPULACE

Zakázané je xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx x xxxxxx xx účelem xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx a/nebo úprava Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx více xxx xxxxxx 100 ml xx 12 hodin xxxxx xxxxxx legitimně xxxxxxxxx v průběhu xxxxxxxxxxxx xxxxxxxx, chirurgických xxxxxxx xxxx klinických xxxxxxxxxxxxxx xxxxxxxxx.

X3. GENOVÝ X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx, xxxxx xxxxx změnit xxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx mechanismem. Xx mimo xxxx xxxxxxxx technologie xxxxx xxxx, xxxxxxxxx genů x xxxxxxxxxxx přenosů xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx x výjimkou xxxxx xxxxxxxxx x S6.A, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx látky x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, např. x- x x-, xxxx zakázána.

Stimulancia xxxxxxxx:

X6.X: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx v xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: SPECIFICKÁ XXXXXXXXXXX

Xxxx xxxx včetně:

•	2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, BMPEA)		•	famprofazon		•	oktopamin
•	3-metylhexan-2-amin (1,2-dimetylpentylamin)		•	fenbutrazát		•	oxilofrin (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx a xxxx analogy, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (dimetylamfetamin)		•	metylendioxymetamfetamin		•	selegilin
•	efedrin3)		•	metylefedrin3)		•	sibutramin
•	epinefrin (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát]		•	solriamfetol
•	etamivan		•	metylfenidát		•	strychnin
•	etylfenidát		•	niketamid		•	tenamfetamin (metylendioxyamfetamin)
•	etylamfetamin		•	norfenefrin		•	tuaminoheptan
•	etilefrin		•	oktodrin (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, tramazolin, xxxxxxxxxxxxx) x xxxxxxxxxxx zařazená xx Xxxxxxxxxxxxxx xxxxxxxx 2024⁵⁾.

X7 NARKOTIKA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx.

Xxxxxxxx xxxxx v xxxx xxxxx: xxxxxxxxx (heroin)

Následující xxxxxxxxx, xxxxxx jejich xxxxxxxxxx všech xxxxxxxxx xxxxxxx, xxxx. d- x l, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x jeho xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 XXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx. Návykové xxxxx x této xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx kanabinoidy xxxx xxxxxxxx, xxxx.

• x konopí (hašiš, xxxxxxxxx) a xxxxxxxxx xxxxxxxxxx

• xxxxxxxx a xxxxxxxxxx tetrahydrokanabionoly (XXX)

• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx jakoukoliv xxxxxxxx, perorální [xxxxxx xxxxxxxxxx (xxxx. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx cestou.

Mimo xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x topického: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx se používají x rámci xxxxxxxx xxxxxxxxxxxx dávek x xxxxxxxxxxxxxx xxxxxxxx.

X1 BETA-BLOKÁTORY

ZAKÁZANÉ X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx látky v xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx x xxx xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• lukostřelba (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – skoky xx xxxxxx, xxxxxxxxxxx skoky / X-xxxxx x xxxxxxxxx X-xxxxx / xxx air

• automobilový xxxxx (FIA)

• xxxxxxxx xxxxxx (XXXX)* v xxxxxxxxxxxx volného xxxxxxxx, xxxx xxxxxxxx x xxxxxxx xx terč

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• xxxxx (XXX)

• xxxx (XXX)

• minigolf (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx xxxxxx

Xxxx jiné xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx xxxxxxx v xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx zakázaný xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 5 xxxxxxxxxx x 1 ml.

²⁾ xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx koncentraci v xxxx xxxxx než 150 xxxxxxxxxx x 1 xx.

³⁾ xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx x xxxx vyšší než 10 xxxxxxxxxx x 1 xx.

⁴⁾ epinefrin (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, oční, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx programu 2024 x nejsou xxxxxxxxxx xx Xxxxxxxx látky.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Sb. nabyl xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx právních norem xxxxxx právních předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu